Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081876 | SCV000113811 | uncertain significance | not provided | 2013-10-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002313737 | SCV000848670 | uncertain significance | Inborn genetic diseases | 2018-12-07 | criteria provided, single submitter | clinical testing | The c.11825_11827dupATG variant (also known as p.D3942dup), located in coding exon 61 of the VPS13B gene, results from an in-frame duplication of ATG at nucleotide positions 11825 to 11827. This results in the duplication of an aspartate residue between codons 3942 and 3943. This duplication (reported as p.D3942_G3943insD) was detected in compound heterozygous state with a gross deletion encompassing exons 1 to 17 of VPS13B and exon 4 of ORS2 in a patient with developmental delay and cardiac defect (Rivera-Brugués N et al. J. Med. Genet., 2011 Feb;48:136-40). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by PROVEAN in silico analysis (Choi Y et al., PLoS ONE 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Center for Genomics, |
RCV000050055 | SCV000899088 | uncertain significance | Cohen syndrome | 2021-09-17 | criteria provided, single submitter | clinical testing | VPS13B NM_017890.4 exon 62 p.Asp3942_dup (c.11825_11827dupATG): This variant has been reported in the literature as a compound heterozygote (in trans with a multi-exon deletion of this gene) in 1 individual with a diagnosis of Cohen syndrome (Rivera-Brugues 2011 PMID:20921020, gene identified as alternate name COH1). However, this variant is present in 0.4% (100/24024) of African alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/rs558633643). This variant is present in ClinVar (Variation ID:56642). Evolutionary conservation and computational predictive tools for this variant are limited or unavailable. This variant represents a duplication of 1 amino acid at position 3942 and is not predicted to alter the reading frame. However, the effect of this variant on the protein is unclear. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. |
Labcorp Genetics |
RCV000050055 | SCV000963968 | likely benign | Cohen syndrome | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000050055 | SCV001137692 | uncertain significance | Cohen syndrome | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000081876 | SCV001819828 | likely benign | not provided | 2021-02-26 | criteria provided, single submitter | clinical testing | In-frame insertion of one amino acid in a non-repeat region; Reported previously using alternate nomenclature (c.1827_11828insATG) in an individual with developmental delay, cardiac defects, and dysmorphic features who harbored a partial gene deletion on the opposite allele (in trans) (Rivera-Brugues et al., 2011); This variant is associated with the following publications: (PMID: 20921020) |
Revvity Omics, |
RCV000050055 | SCV003820436 | uncertain significance | Cohen syndrome | 2019-08-06 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003982870 | SCV004799517 | likely benign | VPS13B-related disorder | 2022-03-18 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000050055 | SCV000082464 | probable-pathogenic | Cohen syndrome | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |